# KC-WISE (KN026): what clinicians are saying

> 77 statements from 25 sources (2 videos, 23 posts), 26 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026.

## Report

- Trial: A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.
- NCT ID: NCT05427383
- Registry: https://clinicaltrials.gov/study/NCT05427383
- Sponsor: Shanghai JMT-Bio Inc.
- Phase: Phase 2/Phase 3
- Status: Recruiting
- Drugs tested: KN026
- Indication: HER2-positive advanced gastric cancer after failed first-line therapy
- Version: v1.0.0, edition 1
- Accepted: 2026-11-19 UTC
- Last checked: 2026-11-19 UTC
- Release hash: 036d532bb7b86680e2d49f8c92b082e2e6aca5df96075cc1553e271d3d86cd14

## Counts

- Commentary sources screened: 43
- Sources cited by verified statements: 25
- Verified statements: 77
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 26
- Findings: 8
- Named people in screened sources (unnamed speakers and accounts not counted): 13
- Speakers cited: 13
- Cited speakers with a verified identity: 12
- Cited clinicians, speakers with a confirmed clinical role (the abstract's clinicians): 7
- Of them physicians, whose confirmed role is a physician's, not a physician assistant's, nurse's or pharmacist's (the abstract's physicians): 7
- By role and specialty (the abstract's specialty counts):
  - 5 physician, Medical oncology
  - 1 physician, specialty not confirmed
  - 1 physician, Gastroenterology
- Organisational or shared accounts (not counted as people): 2

A verified identity says who a speaker is. A cited clinician also has a clinical role confirmed by the NPI registry or their own institution's staff page. Verified speakers without such a role, such as researchers, advocates, company staff, or clinicians whose role only a source or their own profile states, are not counted as clinicians.

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

A medical oncologist reads KC-WISE as a signal for changing care, citing benefit from continued HER2 targeting; another considers the interim overall-survival data too immature for that judgment. A physician leans toward T-DXd for now, while considering later anbenitamab for patients with lung disease. Differences among secondary accounts remain unresolved without an original results publication in the sources reviewed. The sources place interim results at ESMO 2025 and the updated OS analysis at ESMO 2026.

## Question clinicians left open

What do clinicians need from mature overall-survival follow-up and global validation to decide whether KC-WISE’s anbenitamab plus chemotherapy should change practice after trastuzumab failure in HER2-positive gastric/GEJ cancer?

From finding F1 (11 statements from 5 speakers in 7 sources). The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. KC-WISE: where speakers split on readiness to change practice
  - 11 statements from 5 speakers in 7 sources.
  - 5 of the 5 named speakers in this finding take a side on this question: 1 on one side, 4 on the other.
  - 3 of the report's 7 cited clinicians.
- F2. KC-WISE results: how speakers weigh the chemotherapy-only comparator
  - 5 statements from 3 speakers in 3 sources.
  - 3 of the 3 named speakers in this finding hold this view.
  - 2 of the report's 7 cited clinicians.
- F3. KN026 beyond T-DXd: what speakers say
  - 8 statements from 4 speakers in 5 sources.
  - 3 of the report's 7 cited clinicians.
- F4. KC-WISE safety: where speakers split on added toxicity versus chemotherapy alone
  - 20 statements from 11 speakers in 17 sources, 2 of them podcasts or videos.
  - 8 of the 11 named speakers in this finding take a side on this question: 2 on one side, 7 on the other, 1 on both.
  - 6 of the report's 7 cited clinicians.
- F5. KC-WISE curves: why a speaker looks beyond medians for long-term outcomes
  - 8 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.
- F6. Dual HER2 targeting: what most speakers highlight, while some use ADC terms
  - 31 statements from 10 speakers in 17 sources, 2 of them podcasts or videos.
  - 9 of the 10 named speakers in this finding hold this view; 2 of them hold its caveat, “some use ADC terms”.
  - 4 of the report's 7 cited clinicians.

### Beyond the trial population

- F7. Chemotherapy with KN026: a speaker thinks it is probably unnecessary in routine care
  - 5 statements from 2 speakers in 3 sources, 1 of them a podcast or video.
  - 1 of the 2 named speakers in this finding holds this view.
  - 1 of the report's 7 cited clinicians.
- F8. KN026 at lower HER2 expression: why a speaker expects activity
  - 4 statements from 1 speaker in 1 source, a podcast or video.
  - The one named speaker in this finding holds this view.
  - No named clinician · accounts and unnamed speakers.

2 of the 8 findings and 7 of the 77 statements are about other patients, lines of treatment or settings. The report lists them after the trial findings under “Beyond the trial population”, as this page does.

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding. Speakers are the named people a finding's statements cite, of any role, counted as the report counts its cited speakers; unnamed speakers and accounts are not counted.

| Finding | Statements | Passages | Sources | Speakers | Limitations |
| --- | ---: | ---: | ---: | ---: | ---: |
| F1 | 11 | 9 | 7 | 5 | 2 |
| F2 | 5 | 3 | 3 | 3 | 2 |
| F3 | 8 | 5 | 5 | 4 | 2 |
| F4 | 20 | 20 | 17 | 11 | 3 |
| F5 | 8 | 11 | 1 | 1 | 2 |
| F6 | 31 | 22 | 17 | 10 | 3 |
| F7 | 5 | 4 | 3 | 2 | 3 |
| F8 | 4 | 8 | 1 | 1 | 4 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Statement links to supporting passages | Statement links to context passages | Sources by kind |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- |
| F1 | 10 | 0 | 0 | 0 | 1 | 14 | 0 | 7 posts and articles |
| F2 | 2 | 0 | 0 | 3 | 0 | 5 | 0 | 3 posts and articles |
| F3 | 6 | 0 | 0 | 2 | 0 | 8 | 0 | 5 posts and articles |
| F4 | 12 | 0 | 0 | 2 | 6 | 24 | 0 | 15 posts and articles, 2 podcasts and video |
| F5 | 7 | 0 | 0 | 0 | 1 | 12 | 2 | 1 podcast or video |
| F6 | 22 | 0 | 1 | 1 | 7 | 34 | 1 | 15 posts and articles, 2 podcasts and video |
| F7 | 4 | 0 | 0 | 0 | 1 | 6 | 0 | 2 posts and articles, 1 podcast or video |
| F8 | 3 | 1 | 0 | 0 | 0 | 8 | 0 | 1 podcast or video |

### Trial dimensions

- Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC: F1 (6 shared claims), F2 (2 shared claims), F4 (10 shared claims), F5 (5 shared claims), F6 (11 shared claims)
- Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC: F1 (7 shared claims), F2 (2 shared claims), F3 (1 shared claims), F4 (11 shared claims), F5 (3 shared claims), F6 (12 shared claims)
- Secondary endpoints: F1 (2 shared claims), F4 (13 shared claims), F5 (1 shared claims), F6 (8 shared claims)
- Population and setting: F1 (6 shared claims), F2 (2 shared claims), F3 (1 shared claims), F4 (2 shared claims), F6 (2 shared claims)
- The comparison: F1 (4 shared claims), F2 (4 shared claims), F3 (3 shared claims), F4 (4 shared claims), F6 (4 shared claims)
- Safety and tolerability: F1 (2 shared claims), F2 (1 shared claims), F3 (1 shared claims), F4 (17 shared claims), F5 (1 shared claims), F6 (4 shared claims)
- Design and conduct: F1 (8 shared claims), F2 (2 shared claims), F3 (1 shared claims), F4 (2 shared claims), F6 (2 shared claims)

## Abbreviations

- ADC: antibody–drug conjugate
- ESMO: European Society for Medical Oncology
- GEJ: gastroesophageal junction
- HCP: healthcare professional
- HER2: human epidermal growth factor receptor 2
- IRC: independent review committee
- MCP: Model Context Protocol, how AI agents read the report
- NPI: National Provider Identifier, the US registry number for clinicians
- OS: overall survival
- PFS: progression-free survival
- RECIST: Response Evaluation Criteria in Solid Tumors
- T-DXd: trastuzumab deruxtecan

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 8 | Titles free |
| Detailed analysis | 10 sections | Paid |
| Verified statements with short source quotes and links | 77 | Paid |
| Who said each statement: the cited speakers | 13 | Every edition |
| Speakers with a clinical role confirmed by the NPI registry or a staff page | 7 | Every edition |
| Speakers with verified IDs as data (NPI, ORCID, staff page) | 12 | Every edition |
| CMS-reported financial relationships (Open Payments, by company) for NPI-linked speakers | Included | Every edition |
| Trial aspects mapped | 13 | Free |
| Sources with links | 25 | Counts free |
| MCP access for your AI agent, same license key | Included | Every edition |

Every edition, the free report included, names who said each statement, as the source shows them. Each named speaker's card gives a clinical role only when the NPI registry or the person's own institution's staff page confirms it, and says which; a role only a source states is labelled as the source's. Here 7 of the 13 cited speakers have a role confirmed that way. Every edition also comes with MCP access, so your AI agent reads the same evidence with your license key, and with verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself. Social accounts are not included. The IDs are for checking attribution inside your organization. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.

## Trial aspects

13 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC | discussed | 24 | 19 |
| Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC | discussed | 24 | 20 |
| Secondary endpoints | discussed | 19 | 16 |
| Population and setting | discussed | 9 | 7 |
| The comparison (The registered arms and what clinicians said about how they compare.) | discussed | 11 | 8 |
| Safety and tolerability | discussed | 17 | 16 |
| Design and conduct | discussed | 9 | 6 |
| Clinical readiness, global validation and HER2 reassessment | discussed | 11 | 7 |
| Post-trastuzumab alternatives, access and HER2-treatment sequencing | discussed | 10 | 7 |
| Dual-epitope rationale and drug-class terminology | discussed | 20 | 9 |
| Survival-curve interpretation and communication | discussed | 8 | 1 |
| Chemotherapy-free extrapolation outside the tested regimen | discussed | 5 | 3 |
| Lower-HER2 predictions, testing labels and patient support | discussed | 4 | 1 |

Discussed means at least one verified statement addresses the aspect, not that every question in it is covered: gaps inside a discussed aspect are listed under Scope and limits, and the full report gives each aspect its own limitations. No commentary found means none in the sources read. Assessment incomplete marks an aspect with no statement found while known source limits apply.

## Sources

| Channel | Statements | Cited | Screened |
| --- | ---: | ---: | ---: |
| **Video & audio · 33 statements · 43%** | | | |
| YouTube | 33 | 2 | 2 |
| **Posts · 44 statements · 57%** | | | |
| X threads | 43 | 22 | 40 |
| LinkedIn posts | 1 | 1 | 1 |

- Screened window: 2025-09-27 to 2026-11-01
- Cited window: 2025-10-16 to 2026-10-23
- Retrieved: 2026-11-19

Statements count each verified statement once, split evenly over the sources it cites. Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Randomized, Multicenter, Phase Ⅱ/Ш Clinical Study to Evaluate the Efficacy of KN026 in Combination With Chemotherapy in Subjects With HER2 Positive Advanced Unresectable or Metastatic Gastric Cancer (Including Gastro-esophageal Junction Adenocarcinoma) Who Have Failed First-line Therapy.
- Registry: NCT05427383 (https://clinicaltrials.gov/study/NCT05427383)
- Study IDs: KN026-001
- Sponsor: Shanghai JMT-Bio Inc.
- Design: Phase 2/Phase 3 · interventional, randomized, parallel, phase2, phase3
- Status: Recruiting
- Enrollment: 286 (estimated)
- Start: 2022-04-07 (actual)
- Primary completion: 2025-11 (estimated)
- Primary endpoint: Progression Free Survival (PFS) according to RECIST 1.1 by IRC (Up to 2.5 years)
- Primary endpoint: Overall Survival (OS) according to RECIST 1.1 by IRC (Up to 2.5 years)
- Intervention: KN026/Placbo Injection (drug)
- Intervention: Paclitaxel Injection (drug)
- Intervention: Docetaxel Injection (drug)
- Intervention: Irinotecan Injection (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- 1 matching source (1 X thread) could not be read and is not included.
- Not yet captured in this edition: a view on the survival-benefit versus toxicity trade-off of antibody plus chemotherapy after first-line treatment.
- 1 passage in 1 source used in this report was not fully assessed for clinician views, so a view there may be missing from this edition.
- 25 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: 44 sources about other trials or topics are not included.
- This report characterizes the sources reviewed for this edition, not all HCP discussion or the prevalence of any opinion. Repeated posts and reposts are not independent endorsements.
- Potentially relevant discussion may be missing where the trial or KN026 is not named or is described differently. One X conversation could not be read, and part of a video was not fully assessed.
- No full protocol or original trial results publication is included. Linked article information and secondary summaries cannot independently resolve disagreements about study conduct or results.
- Authors report different response rates, event definitions and analysis populations. These accounts are kept distinct rather than pooled into one results summary.
- Some comments about survival-curve interpretation, stratification and Canadian prescribing have no identifiable speaker. They cannot be assigned to a named speaker or counted as independent agreement.
- Product-specific regulatory information is incomplete. Statements about historical approval, availability or prescribing remain attributed accounts, not independently established regulatory conclusions.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, edition 1, accepted 2026-11-19 UTC: current edition
  - Routine maintenance: 1 fix (tags):
    - 2026-11-19 UTC: taxonomy mapping corrected

Each new edition gets a new version: a new or changed finding raises the middle number (1.0.0 to 1.1.0), added evidence or newly verified speakers alone the last number (1.0.0 to 1.0.1), and a change of report format the first number. A correction fixes the published edition in place without making a new edition, so the version stays the same. Changes are corrections that add, remove or change a statement or finding, or withdraw a source; routine maintenance (people cards, names and spellings, recounts, tags and page wording) changes none. Every correction is listed here with its date. Last checked for new commentary 2026-11-19 UTC. No changes.

## Offer

- Size: Focused · 77 verified statements · 26 from 7 confirmed clinicians
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of updates: $1,300
- 6 months of updates: $1,900
- 12 months of updates: $2,600
- Every product includes verified IDs for each identity-checked speaker (the NPI, ORCID and OpenAlex IDs, and their institution's staff page), so your team can check each attribution itself (12 identity-verified speakers now); social accounts are not included. Allowed: advisory boards, scientific exchange and finding investigators, under your own compliance process. Not allowed: sales or marketing to clinicians.
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/kc-wise-nct05427383
- Agents: POST https://www.erudio.com/api/orders with {"report": "kc-wise-nct05427383", "product": "edition" | "updates-3" | "updates-6" | "updates-12", "buyer_email": "...", "organization": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user and a pay_url your own payment client can pay over HTTP 402 in USDC, with MPP (on Tempo) or x402 (on Base), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=kc-wise-nct05427383

## Cite

Erudio Health. KC-WISE (NCT05427383): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 19, 2026. https://www.erudio.com/reports/kc-wise-nct05427383

## Questions

### How much does the KC-WISE report cost?

One edition costs $750 (Focused · 77 verified statements · 26 from 7 confirmed clinicians). With updates: 3 months $1,300, 6 months $1,900, 12 months $2,600. Subscriptions are prepaid, and the price is fixed for the term you buy, even if a new edition moves the trial up a size. Nothing renews automatically: a new term is bought at the price then current.

### What does the KC-WISE report cover?

77 statements from 25 sources (2 videos, 23 posts), 26 of them from 7 confirmed clinicians, each linked to its source. Commentary checked Nov 19, 2026. The report separates what clinicians said from what primary sources establish; it does not judge efficacy or estimate consensus.

### Can my AI agent read or buy the KC-WISE report?

Yes. On https://mcp.erudio.com/free, with no sign-in, get_report_card({ "slug": "kc-wise-nct05427383" }) previews it and create_order({ "report": "kc-wise-nct05427383", "product": "edition", "buyer_email": "<work email>" }) orders it. Once paid, the license key reads it with read_report on https://mcp.erudio.com/mcp. [Connect your AI client](https://www.erudio.com/developers/connect)

### How current is the KC-WISE report?

Edition 1 (version 1.0.0), accepted Nov 19, 2026 UTC; last checked for new commentary Nov 19, 2026 UTC. Your plan includes every new edition published during its term. We automatically check subscribed trials for new commentary every week.

## Machine access

- JSON: https://www.erudio.com/reports/kc-wise-nct05427383.json
- Markdown: https://www.erudio.com/reports/kc-wise-nct05427383.md
- Change feed (JSON Feed: new editions and changes): https://www.erudio.com/reports/kc-wise-nct05427383/feed.json
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "kc-wise-nct05427383"}`
